Cardiac Safety of Novel Obesity Drug BI 456906 Assessed in Phase 1 Trial
A Study to Test Whether Multiple Doses of BI 456906 Have an Effect on Cardiac Safety in People With Overweight or Obesity
Background
BI 456906 is a novel investigational compound currently under development by Boehringer Ingelheim, targeting the widespread conditions of overweight and obesity. Given the potential for chronic administration and the large patient population, a thorough evaluation of cardiac safety is an indispensable early step in its clinical development. This Phase 1 trial was specifically designed to rigorously assess the effects of multiple subcutaneous doses of BI 456906 on various cardiac safety parameters, addressing a critical knowledge gap regarding its cardiovascular profile in otherwise healthy individuals.
Study Design
Population
Healthy individuals who are overweight or obese participated in this Phase 1 trial.
Intervention
Multiple subcutaneous doses of BI 456906 were administered.
Outcome
The primary outcome measured was the effect of BI 456906 on various cardiac safety parameters.